[go: up one dir, main page]

AR066105A1 - Utilizacion de 4- cicloproilmetoxi-n-(3,5- dicloro-1- oxido-4- piridin-4-il)-5-( metoxi) piridin -2- carboxamida para el tratamiento de los traumatismos craneales - Google Patents

Utilizacion de 4- cicloproilmetoxi-n-(3,5- dicloro-1- oxido-4- piridin-4-il)-5-( metoxi) piridin -2- carboxamida para el tratamiento de los traumatismos craneales

Info

Publication number
AR066105A1
AR066105A1 ARP080101599A ARP080101599A AR066105A1 AR 066105 A1 AR066105 A1 AR 066105A1 AR P080101599 A ARP080101599 A AR P080101599A AR P080101599 A ARP080101599 A AR P080101599A AR 066105 A1 AR066105 A1 AR 066105A1
Authority
AR
Argentina
Prior art keywords
piridin
oxido
carboxamide
treatment
cycloproilmetoxi
Prior art date
Application number
ARP080101599A
Other languages
English (en)
Inventor
Luc Even
Christian Hoornaert
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819821&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR066105(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR066105A1 publication Critical patent/AR066105A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Utilizacion de 4-ciclopropilmetoxi-N-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para la preparacion de un medicamento destinado al tratamiento de los traumatismos cerebrales.
ARP080101599A 2007-04-19 2008-04-18 Utilizacion de 4- cicloproilmetoxi-n-(3,5- dicloro-1- oxido-4- piridin-4-il)-5-( metoxi) piridin -2- carboxamida para el tratamiento de los traumatismos craneales AR066105A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702852A FR2915099B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens

Publications (1)

Publication Number Publication Date
AR066105A1 true AR066105A1 (es) 2009-07-22

Family

ID=38819821

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101599A AR066105A1 (es) 2007-04-19 2008-04-18 Utilizacion de 4- cicloproilmetoxi-n-(3,5- dicloro-1- oxido-4- piridin-4-il)-5-( metoxi) piridin -2- carboxamida para el tratamiento de los traumatismos craneales

Country Status (33)

Country Link
US (1) US9393236B2 (es)
EP (1) EP2146713B1 (es)
JP (1) JP5386476B2 (es)
KR (1) KR101460828B1 (es)
CN (1) CN101663036B (es)
AR (1) AR066105A1 (es)
AT (1) ATE532513T1 (es)
AU (1) AU2008257319B2 (es)
BR (1) BRPI0810423A2 (es)
CA (1) CA2684171C (es)
CL (1) CL2008001135A1 (es)
CO (1) CO6140028A2 (es)
CY (1) CY1112282T1 (es)
DK (1) DK2146713T3 (es)
EA (1) EA015503B1 (es)
ES (1) ES2376023T3 (es)
FR (1) FR2915099B1 (es)
HR (1) HRP20120130T1 (es)
IL (1) IL201447A (es)
JO (1) JO2861B1 (es)
MA (1) MA31368B1 (es)
ME (2) ME01273B (es)
MX (1) MX2009011214A (es)
MY (1) MY147207A (es)
NZ (1) NZ580484A (es)
PA (1) PA8776701A1 (es)
PL (1) PL2146713T3 (es)
PT (1) PT2146713E (es)
RS (1) RS52130B (es)
SI (1) SI2146713T1 (es)
TW (1) TWI423800B (es)
UY (1) UY31034A1 (es)
WO (1) WO2008145838A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006807A (es) * 2012-11-28 2016-01-14 Sanofi Sa Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1273326A (en) * 1917-08-22 1918-07-23 George H Bugenhagen Transmission mechanism.
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE69430747T2 (de) 1993-07-28 2003-03-06 Aventis Pharma Ltd., West Malling Verbindungen als pde iv und tnf inhibitoren
GB9401460D0 (en) * 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9507297D0 (en) * 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU6428400A (en) * 1999-06-07 2000-12-28 Warner-Lambert Company Tricyclic analgesics
EP1244649B1 (en) * 1999-12-23 2005-03-02 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
AU2003281219A1 (en) 2002-07-02 2004-01-23 Bernard Cote Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004067006A1 (en) * 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
CA2541299A1 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury
FR2915098B1 (fr) 2007-04-19 2009-06-05 Sanofi Aventis Sa Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Also Published As

Publication number Publication date
PL2146713T3 (pl) 2012-04-30
BRPI0810423A2 (pt) 2014-10-14
MA31368B1 (fr) 2010-05-03
MY147207A (en) 2012-11-14
HRP20120130T1 (hr) 2012-03-31
PT2146713E (pt) 2012-02-07
AU2008257319B2 (en) 2013-07-25
TWI423800B (zh) 2014-01-21
CN101663036A (zh) 2010-03-03
CY1112282T1 (el) 2015-12-09
TW200914009A (en) 2009-04-01
SI2146713T1 (sl) 2012-03-30
CL2008001135A1 (es) 2009-01-16
CN101663036B (zh) 2012-06-20
US9393236B2 (en) 2016-07-19
EA200970968A1 (ru) 2010-02-26
CO6140028A2 (es) 2010-03-19
PA8776701A1 (es) 2008-11-19
US20100130553A1 (en) 2010-05-27
JO2861B1 (en) 2015-03-15
FR2915099B1 (fr) 2009-06-05
JP5386476B2 (ja) 2014-01-15
CA2684171A1 (fr) 2008-12-04
EP2146713B1 (fr) 2011-11-09
ME01273B (me) 2013-06-20
NZ580484A (en) 2011-06-30
MX2009011214A (es) 2009-11-02
DK2146713T3 (da) 2012-03-05
FR2915099A1 (fr) 2008-10-24
IL201447A (en) 2013-07-31
EP2146713A2 (fr) 2010-01-27
CA2684171C (fr) 2015-12-01
HK1141724A1 (en) 2010-11-19
IL201447A0 (en) 2010-05-31
WO2008145838A3 (fr) 2009-03-26
ME00938B (me) 2012-06-20
JP2010524903A (ja) 2010-07-22
UY31034A1 (es) 2008-11-28
RS52130B (sr) 2012-08-31
KR20090130058A (ko) 2009-12-17
EA015503B1 (ru) 2011-08-30
KR101460828B1 (ko) 2014-11-11
ES2376023T3 (es) 2012-03-08
WO2008145838A2 (fr) 2008-12-04
ATE532513T1 (de) 2011-11-15
AU2008257319A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
WO2009012275A9 (en) Pyridone gpr119 g protein-coupled receptor agonists
ECSP067098A (es) Compuestos y metodos para el tratamiento de dislipidemia
GEP20146082B (en) Compositions and methods of wnt signaling modulators
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
AR060880A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
AR059390A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
ITMI20072397A1 (it) Apparecchiatura medicale per il trattamento extracorporeo
AR066106A1 (es) Utilizacion de 4- ciclopropilmetoxi-n-(3,5- dicloro-1- oxido- piridin -4-il)-5- (metoxi) piridin-2- carboxamida para el tratamiento de los traumatismos de la medula espinal
UA101961C2 (xx) Кристалічна форма 1 2-((r)-2-метилпіролідин-2-іл)-1h-бензімідазол-4-карбоксаміду$кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1h-бензимидазол-4-карбоксамида
MX2009013202A (es) Derivados terapeuticos de pirazoloquinolina.
AR066105A1 (es) Utilizacion de 4- cicloproilmetoxi-n-(3,5- dicloro-1- oxido-4- piridin-4-il)-5-( metoxi) piridin -2- carboxamida para el tratamiento de los traumatismos craneales
UY31035A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
FIU20070277U0 (fi) Potilasvaate itseään turhaan riisuville potilaille
UA6623U (en) Method for increasing therapeutic efficacy of clays

Legal Events

Date Code Title Description
FB Suspension of granting procedure